Breast Cancer Research and Treatment (2018) 168:283 https://doi.org/10.1007/s10549-017-4589-6 LE T TER TO THE EDITOR Does tacrolimus have any positive impact on outcome of post‑transplant breast cancer patients? Kadri Altundag Received: 26 October 2017 / Accepted: 22 November 2017 / Published online: 24 November 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2017 Acknowledgements The author has not received any grants. Dear Editor, Compliance with ethical standards I wish to congratulate Jeong and colleagues for their article  in which the characteristics and prognosis of post-trans- Conflict of interest I have no conflict of interest to declare. plant breast cancer (PTBC) patients receiving immunosup- pressants and general breast cancer patients were compared. Ethical approval My manuscript complies with the Ethical Rules appli- They reported that subtype and prognosis of breast cancer cable for this journal. were comparable with that in the general cohort and immu- Research involving human and animal participants This article does nosuppressants do not adversely affect breast cancer prog - not contain any studies with human participants or animals performed nosis. In this study, 24 were diagnosed with PTBC. Of the by the author. 24 PTBC cohort, 12 received mammalian target of rapa- mycin (mTOR) inhibitor—tacrolimus as immunosuppres- sive agent. Results of both the TAMRAD and BOLERO-2 References studies showed that mTOR inhibition in combination with endocrine therapy improved progression-free survival for 1. Jeong IJ, Lee SG, Kim YH, Ko BS, Lee JW, Son BH, Ahn SH, hormone receptor-positive metastatic breast cancer patients Kim HJ (2017) Characteristics and prognosis of breast cancer . For this reason, it would be interesting to compare the after liver or kidney transplantation. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4504-1 outcome of hormone receptor-positive PTBC patients who 2. Sendur MA, Zengin N, Aksoy S, Altundag K (2014) Everolimus: received endocrine treatment and tacrolimus with hormone a new hope for patients with breast cancer. Curr Med Res Opin receptor-positive patients in general cohort. 30(1):75–87. https://doi.org/10.1185/03007995.2013.846253 * Kadri Altundag firstname.lastname@example.org MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey Vol.:(0123456789) 1 3
Breast Cancer Research and Treatment – Springer Journals
Published: Nov 24, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera